跳至主要内容
临床试验/jRCT2080220136
jRCT2080220136未知3 期

Clinical investigation for combination therapy of KAD-1229 and Pioglitazone.

KISSEI PHARMACEUTICAL CO.,LTD.0 个研究点开始时间: 待定

试验速览

阶段
3 期
主要终点
-

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
干预模型
Double-blind, Parallel group comparison

入排标准

年龄范围
20age old over 至 No limit(—)
性别
All

入选标准

  • Main Inclusion Criteria:
  • Type 2 diabetic outpatients, aged 20 years or older, who are treated with diet and stable dose of pioglitazone monotherapy.
  • HbA1c and post prandial glucose are within a certain range
  • Main Exclusion Criteria:
  • Patients who require treatment with insulin.
  • Patients complicated with severe diabetic microangiopathy (neuropathy, retinopathy or nephropathy).
  • Patients complicated with severe cardiac disease, hepatic disease, renal disease or hypertension.

排除标准

  • 未提供

结局指标

主要结局

-

Efficacy, Safety

次要结局

未报告次要终点

研究者

相似试验

Clinical investigation for combination therapy of... | 临床试验